Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on LinkedIn about a paper by Milind Javle et al. published in The Lancet Gastroenterology and Hepatology:
“Results from a phase 2 study of tinengotinib, indicating activity in patients with FGFR2-fusion cholangiocarcinoma that had progressed after prior FGFR inhibitor therapy, were published in The Lancet Gastroenterology and Hepatology.
Tinengotinib is a multi-kinase inhibitor suggested to have activity in the setting of FGFR2 resistance mutations. In cohort A2 of the study, which included 11 patients with FGFR2 fusions with acquired FGFR inhibitor resistance, the ORR was 30%.
These findings support the randomized phase 3 trial FIRST-308, evaluating tinengotinib vs. chemo in patients with cholangiocarcinoma refractory to FGFR inhibitor therapy and one prior line of chemo.
This trial is enrolling at multiple sites in the Sarah Cannon Research Institute network!”
Title: Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
Authors: Milind Javle, Christos Fountzilas, Chih-Yi Liao, Meredith Pelster, Daneng Li, Dustin Deming, Vaibhav Sahai, Lionel Kankeu Fonkoua, Allen Cohn, Parvez Mantry, Donald Richards, Edwin Kingsley, Frank Wu, Peng Peng, Katie Hennessy, Hui Wang, Caixia Sun, Shumao Ni, Jean Fan, Amit Mahipal
You can read the Full Article in The Lancet Gastroenterology and Hepatology.
More posts featuring Erika Hamilton.